OrbiMed’s BioMarin Pharmaceuticals BMRN Stock Holding History

OrbiMed’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-70,000	Closed	-$6.59M	–	155
2018 Q2	$6.59M	Buy	+70,000	New	+$6.13M	0.08%	123

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

OrbiMed's BMRN Position: Q3 2024 in Review

OrbiMed sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 26,100 shares — an estimated $2.15M sold.

OrbiMed first reported a position in BMRN in Q2 2013 and held it in 36 quarters. The position peaked at $167M in Q4 2022. 554 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

OrbiMed reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 26,100 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.15M.
OrbiMed first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 36 quarters.
OrbiMed's BioMarin Pharmaceuticals position peaked at $167M in Q4 2022.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.